Conditions: Pulmonary Disease, Chronic Obstructive
Keywords: muscarinic receptor, bronchodilators Chronic obstructive pulmonary disease,
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 23
Healthy volunteers: no

Brief summary:
GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for the treatment of chronic obstructive pulmonary disease. This is a randomised, double-blind, placebo-controlled, dose ascending, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice daily inhaled doses of GSK233705B for 7 days, in COPD subjects.

Detailed description:

Arms:

Interventions: intervention 1: GSK233705B
Intervention descriptions: intervention 1: None

Protocol document: